Aniracetam
3 sources
🧬 Receptor activity
| Target | Action | Affinity | Source | |
|---|---|---|---|---|
| GluA1 | Positive (Allosteric modulator) | — | GTOPDB | TargetGluA1 ActionPositive (Allosteric modulator) Affinity— SourceGTOPDB |
| GluA2 | Positive (Allosteric modulator) | — | GTOPDB | TargetGluA2 ActionPositive (Allosteric modulator) Affinity— SourceGTOPDB |
| GluA3 | Positive (Allosteric modulator) | — | GTOPDB | TargetGluA3 ActionPositive (Allosteric modulator) Affinity— SourceGTOPDB |
| GluA4 | Positive (Allosteric modulator) | — | GTOPDB | TargetGluA4 ActionPositive (Allosteric modulator) Affinity— SourceGTOPDB |
Pharmacodynamics
Aniracetam possesses a wide range of anxiolytic properties, which may be mediated by an interaction between cholinergic, dopaminergic and serotonergic systems.
Pharmacokinetics
Half-life
1-2.5 hours
External links
PubChem 2196 ↗CAS 72432-10-1 ↗KEGG C13355 ↗ChEBI CHEBI:47943 ↗ChEMBL CHEMBL36994 ↗KEGG D01883 ↗DrugBank DB04599 ↗NIH ↗ChemSpider ↗ChEBI/ChEMBL ↗ChEBI/ChEMBL ↗Guide to Pharmacology ↗NIH ↗NIH ↗NIH ↗DrugBank ↗ChEBI/ChEMBL ↗CAS 1235-82-1 ↗CAS 27670-93-5 ↗PsychonautWiki ↗Erowid ↗Experience reports (PiHKAL) ↗Experience reports (TiHKAL) ↗
Fact-sheets from PsychonautWiki. Harm-reduction reference only — not medical advice.